Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress
Clinical Collections
Advances in Alzheimer’s

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.
ADVANCED SEARCH
Log in
Top
BMC Urology
Published in: BMC Urology 1/2015

Open Access 01-12-2015 | Research article

Benign prostatic hyperplasia complicated with T1DM can be alleviated by treadmill exercise—evidences revealed by the rat model

Authors: Kuan-Chou Chen, Shian-Ying Sung, Yi-Ting Lin, Chiu-Lan Hsieh, Kun-Hung Shen, Chiung-Chi Peng, Robert Y. Peng

Published in: BMC Urology | Issue 1/2015

Login to get access

Abstract

Background

Both benign prostatic hyperplasia (BPH) and Type-1 diabetes mellitus (T1DM) share similar epidemiologic features and are all associated with the insulin-like growth factor (IGF)-mediated hormonal imbalance. The purpose of this study is to understand whether exercise (EX) could alleviate DM and DM + BPH.

Methods

Sprague-Dawley rats were divided into eight groups: normal control, EX, BPH, BPH + EX, DM, DM + EX, BPH + DM, and BPH + DM + EX. T1DM was induced by intraperitoneal (ip) injection of streptozotocin (65 mg/kg) in Week 2, and BPH was induced by successive ip injections of Sustanon® (testosterone, 3.5 mg/head) plus estradiol (0.1 mg/head) from Week 3 to Week 9. Treadmill exercise training (20 m/min, 60 min per time) was performed three times per week for 6 weeks.

Results

In BPH + EX, EX maintained at a constant body weight (BW); and suppressed stromal layer thickening, collagen deposition, blood glucose (BG), levels of testosterone (Ts), 5α-reductase(5αRd), dihydrotestosterone (DHT), androgen receptor (AR), serum hydrogen peroxide, TBARs, and interleukin-6 (IL-6). EX recovered testes size and substantially increased nitric oxide (NO) levels. In DM + EX group, EX decreased BW, PW, nuclear proliferation, inflammatory cell aggregation, collagen deposition, and BG. As contrast, EX upregulated insulin, IGF, Ts, NO, 5αRd, AR, and DHT, and substantially reduced PSA. In BPH + DM + EX, EX maintained BW at a subnormal level, slightly suppressed prostate stromal inflammation, collagen deposition, and BG, moderately restored sIn and IGF. Although failed to suppress Ts, EX highly upregulated 5αRd and suppressed DHT and AR, together with highly upregulated NO resulting in substantially reduced PSA.

Conclusion

EX, by remodeling androgen and NO expressions, can effectively alleviate BPH, DM, and BPH + DM.
Literature
1.
Gacci M, Vignozzi L, Sebastianelli A, Salvi M, Giannessi C, De Nunzio C, et al. Metabolic syndrome and lower urinary tract symptoms: the role of inflammation. Prostate Cancer Prostatic Dis. 2013;16:101–6.CrossRefPubMed
2.
Wang Z, Olumi AF. Diabetes, growth hormone-insulin-like growth factor pathways and association to benign prostatic hyperplasia. Differentiation. 2011;82:261–71.CrossRefPubMed
3.
Zinman B, Ruderman N, Campaigne BN, Devlin JT, Schneider SH. Physical activity/exercise and Diabetes Mellitus. Diabetes care. 2003;26 Suppl 1:S73–7.PubMed
4.
Sarma AV, Kellogg PJ. Diabetes and benign prostatic hyperplasia: emerging clinical connections. Curr Urol Rep. 2009;10:267–75.CrossRefPubMed
5.
de Lemos ET, Oliveira J, Pinheiro JP, Reis F. Regular Physical Exercise as a Strategy to improve antioxidant and anti-Inflammatory status: Benefits in type 2 diabetes mellitus. Oxidative Med and Cellu Longevity. 2012;741545:1–15.CrossRef
6.
7.
Peng CC, Liu JH, Chang CH, Chung JY, Chen KC, Chou KY, et al. Action mechanism of Ginkgo biloba leaf extract intervened by exercise therapy in treatment of benign prostate hyperplasia. Evid Based Complement Alternat Med. 2013;408734:1–12.CrossRef
8.
Sea J, Poon KS, McVary KT. Review of exercise and the risk of benign prostatic hyperplasia. Phys Sports med. 2009;37:75–83.CrossRef
9.
10.
Ronald JS, Glen PK, David HW, Carmen C-S, Russell DW. Physical Activity/Exercise and Type 2 Diabetes: A consensus statement from the American Diabetes Association. Diabetes Care. 2006;29:1433–8.CrossRef
11.
Bird SR, Hawley JA. Exercise and type 2 diabetes: new prescription for an old problem. Maturitas. 2012;72:311–6.CrossRefPubMed
12.
Stamatiou K, Lardas M, Kostakos E, Koutsonasios V, Michail E. The impact of diabetes type 2 in the pathogenesis of benign prostatic hyperplasia: a review. Adv Urol. 2009;818965:1–3.CrossRef
13.
Parsons JK, Carter HB, Partin AW, Windham BG, Metter EJ, Ferrucci L, et al. Metabolic factors associated with benign prostatic hyperplasia. J Clin Endocrinol Metab. 2006;91(7):2562–68.CrossRefPubMedPubMedCentral
14.
Berger AP, Deibl M, Leonhartsberger N, Bektic J, Horninger W, Fritsche G, et al. Vascular damage as a risk factor for benign prostatic hyperplasia and erectile dysfunction. BJU Int. 2005;96(7):1073–8.CrossRefPubMed
15.
Timms BG, Hofkamp LE. Prostate development and growth in benign prostatic hyperplasia. Differentiation. 2011;82:173–83.CrossRefPubMed
16.
Untergasser G, Madersbacher S, Berger P. Benign prostatic hyperplasia: age-related tissue-remodeling. Exp Gerontol. 2005;40:121–8.CrossRefPubMed
17.
Ikeda K, Wada Y, Foster Jr HE, Wang Z, Weiss RM, Latifpour J. Experimental diabetes-induced regression of the rat prostate is associated with an increased expression of transforming growth factor-beta. J Urol. 2000;164:180–5.CrossRefPubMed
18.
Porto EM, Dos Santos SA, Ribeiro LM, Lacorte LM, Rinaldi JC, Justulin Jr LA, et al. Lobe variation effects of experimental diabetes and insulin replacement on rat prostate. Microsc Res Tech. 2011;74:1040–8.CrossRefPubMed
19.
Bostanci Y, Kazzazi A, Momtahen S, Laze J, Djavan B. Correlation between benign prostatic hyperplasia and inflammation. Curr Opin Urol. 2013;23:5–10.CrossRefPubMed
20.
Zhang XH, Filippi S, Morelli A, Vignozzi L, Luconi M, Donati S, et al. Testosterone restores diabetes-induced erectile dysfunction and sildenafil responsiveness in two distinct animal models of chemical diabetes. J Sex Med. 2006;3(2):253–64.CrossRefPubMed
21.
Ochiai A, Fritsche HA, Babaian RJ. Influence of anthropometric measurements, age, and prostate volume on prostate-specific antigen levels in men with a low risk of prostate cancer. Urol. 2005;66:819–23.CrossRefPubMed
22.
Ozden C, Ozdal OL, Urgancioglu G, Koyuncu H, Gokkaya S, Memis A. The correlation between metabolic syndrome and prostatic growth in patients with benign prostatic hyperplasia. Eur Urol. 2007;51:199–203.CrossRefPubMed
23.
Parsons JK, Carter HB, Partin AW, Windham BG, Metter EJ, Ferrucci L, et al. Metabolic factors associated with benign prostatic hyperplasia. J Clin Endocrinol Metab. 2006;91:2562–8.CrossRefPubMedPubMedCentral
24.
Belotto MF, Magdalon J, Rodrigues HG, Vinolo MA, Curi R, Pithon-Curi TC, et al. Moderate exercise improves leukocyte function and decreases inflammation in diabetes. Clin Exp Immunol. 2010;162:237–43.CrossRefPubMedPubMedCentral
25.
Vignozzi L, Gacci M, Cellai I, Santi R, Corona G, Morelli A, et al. Fat boosts, while androgen receptor activation counteracts, BPH-associated prostate inflammation. Prostate. 2013;73:789–800.CrossRefPubMed
26.
Nandeesha H, Koner BC, Dorairajan LN, Sen SK. Hyperinsulinemia and dyslipidemia in non-diabetic benign prostatic hyperplasia. Clin Chim Acta. 2006;370(1-2):89–93.CrossRefPubMed
27.
Hammarsten J, Högstedt B, Holthuis N, Mellström D. Components of the metabolic syndrome-risk factors for the development of benign prostatic hyperplasia. Prostate Cancer Prostatic Dis. 1998;1(3):157–62.CrossRefPubMed
28.
29.
Ribeiro DL, Taboga SR, Góes RM. Diabetes induces stromal remodelling and increase in chondroitin sulphate proteoglycans of the rat ventral prostate. Int J Exp Pathol. 2009;90:400–11.CrossRefPubMedPubMedCentral
30.
Searls YM, Smirnova IV, Fegley BR, Stehno-Bittel L. Exercise attenuates diabetes-induced ultrastructural changes in rat cardiac tissue. Med Sci Sports Exerc. 2004;36:1863–70.CrossRefPubMed
31.
Almeida FN, Proença AR, Chimin P, Marçal AC, Bessa-Lima F, Carvalho CR. Physical exercise and pancreatic islets: acute and chronic actions on insulin secretion. Islets. 2012;4(4):296–301.CrossRefPubMedPubMedCentral
32.
Liu SH, Wang ZS. Study on the expression of androgen receptor in testis, epididymis and prostate of adult rats with diabetes. Zhonghua Nan Ke Xue. 2005;11:891–4.PubMed
33.
Kim WT, Yun SJ, Choi YD, Kim GY, Moon SK, Choi YH, et al. Prostate size correlates with fasting blood glucose in non-diabetic benign prostatic hyperplasia patients with normal testosterone levels. J Korean Med Sci. 2011;26:1214–18.CrossRefPubMedPubMedCentral
34.
Protopsaltis I, Ploumidis A, Sergentanis TN, Constantoulakis P, Tzirogiannis K, Kyprianidou C, et al. Linking pre-diabetes with benign prostate hyperplasia. IGFBP-3: a conductor of benign prostate hyperplasia development orchestra? PLoS One. 2013;8(12):e81411.CrossRefPubMedPubMedCentral
35.
Roberts RO, Jacobson DJ, Girman CJ, Rhodes T, Klee GG, Lieber MM, et al. Insulin-like growth factor I, insulin-like growth factor binding protein 3, and urologic measures of benign prostatic hyperplasia. Am J Epidemiol. 2003;157(9):784–91.CrossRefPubMed
36.
Ho CK, Habib FK. Estrogen and androgen signaling in the pathogenesis of BPH. Nat Rev Urol. 2011;8:29–41.CrossRefPubMed
37.
Sciarra A, Mariotti G, Salciccia S, Autran Gomez A, Monti S, Toscano V, et al. Prostate growth and inflammation. J Steroid Biochem Mol Biol. 2008;108:254–60.CrossRefPubMed
38.
Lucia MS, Lambert JR. Growth factors in benign prostatic hyperplasia: basic science implications. Curr Urol Rep. 2008;9:272–8.CrossRefPubMed
39.
Sudha S, Sankar BR, Valli G, Govindarajulu P, Balasubramanian K. Streptozotocin-diabetes impairs prolactin binding to Leydig cells in prepubertal and pubertal rats. Horm Metab Res. 1999;31:583–6.CrossRefPubMed
40.
41.
Teixeira GR, Fávaro WJ, Pinheiro PF, Chuffa LG, Amorim JP, Mendes LO, et al. Physical exercise on the rat ventral prostate: steroid hormone receptors, apoptosis and cell proliferation. Scand J Med Sci Sports. 2012;22:e86–92.CrossRefPubMed
42.
Timms BG, Chandler JA. Ultrastructural and analytical studies on the prostate of castrated rats. Prostate. 1983;4:37–55.CrossRefPubMed
43.
Vignozzi L, Morelli A, Sarchielli E, Comeglio P, Filippi S, Cellai I, et al. Testosterone protects from metabolic syndrome-associated prostate inflammation: an experimental study in rabbit. J Endocrinol. 2012;212:71–84.CrossRefPubMed
44.
Stamatiadis D, Bulteau-Portois MC, Mowszowicz I. Inhibition of 5 alpha-reductase activity in human skin by zinc and azelaic acid. The Brit J Dermat. 1988;119(5):627–32.CrossRef
45.
Yahya H, Yahya KM, Saqib A. Minerals and type 2 diabetes mellitus –level of zinc, magnesium and chromium in diabetic and non diabetic population. J Univer Med & Dent College. 2011;2:34–8.
46.
Christudoss P, Selvakumar R, Fleming JJ, Gopalakrishnan G. Zinc status of patients with benign prostatic hyperplasia and prostate carcinoma. Indian J Urol. 2011;27(1):14–8.CrossRefPubMedPubMedCentral
47.
Dressendorfer RA, Sockolov R. Hypozincemia in runners. Phys Sports Med. 1980;8:97–100.CrossRef
48.
Sundaram RK, Bhaskar A, Vijayalingam S, Viswanathan M, Mohan R, et al. Antioxidant status and lipid peroxidation in type II diabetes mellitus with and without complications. Clin Sci. 1996;90:255–60.CrossRefPubMed
49.
Wierusz-Wysocka B, Wysocki H, Byks H, Zozulińska D, Wykretowicz A, Kaźmierczak M. Metabolic control quality and free radical activity in diabetic patients. Diabetes Res Clin Practice. 1995;27:193–7.CrossRef
50.
Aryal M, Pandeya A, Gautam N, Baral N, Lamsal M, Majhi S, et al. Oxidative stress in benign prostate hyperplasia. Nepal Med Coll J. 2007;9:222–4.PubMed
51.
Laaksonen DE, Sen CK. Exercise and Oxidative Stress in Diabetes Mellitus. In: Sen CK, Packer L, Hanninen O, editors. Handbook of Oxidants and Antioxidants in Exercise. Amsterdam: Elsevier; 2000. p. 1105–36.CrossRef
52.
53.
Hobisch A, Rogatsch H, Hittmair A, Fuchs D, Bartsch Jr G, Klocker H, et al. Immunohistochemical localization of interleukin-6 and its receptor in benign, premalignant and malignant prostate tissue. J Pathol. 2000;191:239–44.CrossRefPubMed
54.
Okamoto M, Lee C, Oyasu R. Interleukin-6 as a paracrine and autocrine growth factor in human prostatic carcinoma cells in vitro. Cancer Res. 1997;57:141–6.PubMed
55.
Bloch W, Klotz T, Loch C, Schmidt G, Engelmann U, Addicks K. Distribution of nitric oxide synthase implies a regulation of circulation, smooth muscle tone, and secretory function in the human prostate by nitric oxide. Prostate. 1997;33:1–8.CrossRefPubMed
56.
Kedia GT, Uckert S, Jonas U, Kuczyk MA, Burchardt M. The nitric oxide pathway in the human prostate: clinical implications in men with lower urinary tract symptoms. World J Urol. 2008;26:603–9.CrossRefPubMed
57.
De Nunzio C, Aronson W, Freedland SJ, Giovannucci E, Parsons JK. The correlation between metabolic syndrome and prostatic diseases. Eur Urol. 2012;61(3):560–70.CrossRefPubMed
Metadata
Title
Benign prostatic hyperplasia complicated with T1DM can be alleviated by treadmill exercise—evidences revealed by the rat model
Authors
Kuan-Chou Chen
Shian-Ying Sung
Yi-Ting Lin
Chiu-Lan Hsieh
Kun-Hung Shen
Chiung-Chi Peng
Robert Y. Peng
Publication date
01-12-2015
Publisher
BioMed Central
Published in
BMC Urology / Issue 1/2015
Electronic ISSN: 1471-2490
DOI
https://doi.org/10.1186/s12894-015-0104-8

Other articles of this Issue 1/2015

BMC Urology 1/2015 Go to the issue

Research article

The ProCaSP study: quality of life outcomes of prostate cancer patients after radiotherapy or radical prostatectomy in a cohort study

Reviewer acknowledgement

BMC Urology reviewer acknowledgement 2014

Research article

The role of diagnostic ureteroscopy in the era of computed tomography urography

Case report

Penile metastasis of sigmoid colon carcinoma: a rare case report

Research article

Tadalafil 5 mg once daily for the treatment of erectile dysfunction during a 6-month observational study (EDATE): impact of patient characteristics and comorbidities

Research article

Risk factors for biochemical recurrence after robotic assisted radical prostatectomy: a single surgeon experience